CAMERA2 – combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial

BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a serious infection resulting in 20–50 % 90-day mortality. The limitations of vancomycin, the current standard therapy for MRSA, make treatment difficult. The only other approved drug for treatment of MRSA bacteraemia, dap...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Steven Y. C., Nelson, Jane, Paterson, David L., Fowler, Vance G., Howden, Benjamin P., Cheng, Allen C., Chatfield, Mark, Lipman, Jeffrey, Van Hal, Sebastian, O’Sullivan, Matthew, Robinson, James O., Yahav, Dafna, Lye, David, Davis, Joshua S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815121/
https://www.ncbi.nlm.nih.gov/pubmed/27029920
http://dx.doi.org/10.1186/s13063-016-1295-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815121/
https://www.ncbi.nlm.nih.gov/pubmed/27029920
http://dx.doi.org/10.1186/s13063-016-1295-3

Ejemplares similares